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Objective: The prevalence of subclinical contributors to low bone mineral density (BMD) and/or fragility
fracture is debated. We evaluated the prevalence of subclinical contributors to low BMD and/or
fragility fracture in the presence of normal 25-hydroxyvitamin D (25OHVitD) levels.
Design: Prospective observational study.
Methods: Among 1095 consecutive outpatients evaluated for low BMD and/or fragility fractures, 602
(563 females, age 65.4G10.0 years) with apparent primary osteoporosis were enrolled. A general
chemistry profile, phosphate, 25OHVitD, cortisol after 1-mg overnight dexamethasone suppression
test, antitissue transglutaminase and endomysial antibodies and testosterone (in males) were
performed. Serum and urinary calcium and parathyroid hormone levels were also evaluated after
25OHVitD levels normalization. Vertebral deformities were assessed by radiograph.
Results: In total, 70.8% of patients had low 25OHVitD levels. Additional subclinical contributors to
low BMD and/or fragility fracture were diagnosed in 45% of patients, with idiopathic hypercalciuria
(IH, 34.1%) and primary hyperparathyroidism (PHPT, 4.5%) being the most frequent contributors,
apart from hypovitaminosis D. Furthermore, 33.2% of IH and 18.5% of PHPT patients were diagnosed
only after 25OHVitD levels normalization. The subclinical contributors to low BMD and/or fragility
fracture besides hypovitaminosis D were associated inversely with age (odds ratio (OR) 1.02, 95% CI
1–1.04, PZ0.04) and BMI (OR 1.1, 95% CI 1.05–1.17, PZ0.0001) and directly with fragility
fractures (OR 1.89, 95% CI 1.31–2.73, PZ0.001), regardless of BMD.
Conclusions: Subclinical contributors to low BMD and/or fragility fracture besides hypovitaminosis D
are present in more than 40% of the subjects with apparent primary osteoporosis. Hypovitaminosis D
masks a substantial proportion of IH and PHPT patients.
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Osteoporosis encompasses two different forms: primary
and secondary. Primary osteoporosis is due to post-
menopausal and age-related bone loss. Secondary
osteoporosis is defined as bone loss that results from
specific, well-defined, clinical disorders or medical
treatments (1). The prevalence of secondary osteoporo-
sis, in both men and women, is widely debated (1, 2, 3,
4, 5, 6, 7, 8). In some studies 20–30% of postmeno-
pausal women and more than 50% of men with
osteoporosis are affected with the secondary form of
the disease. Some of the secondary causes of osteoporo-
sis may be identified by medical history and/or physical
examination, while others remain hidden unless
additional diagnostic testing is performed. Diagnosing
the subclinical contributors to secondary osteoporosis
is important, since these conditions are reversible withndocrinologyappropriate intervention, leading to a rapid and
substantial increase of bone mineral density (BMD)
(9, 10, 11, 12). On the other hand, if these conditions
are not identified, medical treatment may be suboptimal
or ineffective (1, 13).
Nowadays, guidelines on osteoporosis advocate the
evaluation of osteoporotic patients to identify the
presence of subclinical contributors to secondary
osteoporosis before therapy (8, 14, 15). However, the
diagnostic protocols differ among the various guide-
lines. As a consequence, the actual prevalence of the
subclinical contributors to secondary osteoporosis
remains uncertain, owing to the inclusion of different
populations and different approaches, often not taking
into account all the possible causes (i.e. subclinical
hypercortisolism (SH), celiac disease, etc.) (1, 3, 5, 6,
7, 16). Moreover, the criteria used to define which
patient should undergo additional evaluation (i.e. theDOI: 10.1530/EJE-13-0102
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osteoporosis) are still a matter of debate (17, 18,
19, 20). Finally, no studies have evaluated the patients
after the normalization of serum 25-hydroxyvitamin D
(25OHVitD) levels. This is a crucial point, since
hypovitaminosis D may lead to underestimate the real
prevalence of some diseases, as it may mask the
presence of primary hyperparathyroidism (PHPT) and
idiopathic hypercalciuria (IH) (21, 22).
Therefore, the aim of the present study was to
evaluate, in a large sample of patients, the prevalence
of the different subclinical contributors to low BMD
and/or fragility fracture before and after correction of
hypovitaminosis D.Subjects and methods
Study design, population and inclusion/
exclusion criteria
We prospectively evaluated 1095 patients (937 females
and 158 males) consecutively admitted to our Osteo-
porosis and Metabolic Bone Diseases Outpatients Clinic
from September 2009 to December 2011, and referred
by their primary care physician for reduced BMD and/or
a history of an adult fragility fracture. The inclusion
criteria were the presence of osteopenia or osteoporosis,Primary
osteoporosis
n=331
(55%)
Primary
hyperparathyroidism
n=27
(4.5%)
(before 25OHVitD
 normalization:
n=22, 3.7%)
Idiopathic
hypercalciuria
n=205
(34.1%)
(before 25OHVitD
levels normalization:
n=137, 22.8%)
Hyperthy
n=
(1.3%
427 patients affected with already
known causes of secondary
osteoporosis were excluded
66 patients did not complete the
study protocol
(57 females and 9 males)
1095 consecutive 
males) with prev
BMD (i.e. T-sco
557 patients (6
602 patients (56
apparent idiopath
Figure 1 Study of flow diagram. BMD, bone mineral density; MGUS,
25-hydroxyvitamin D; †among 22 male patients with apparent primary
www.eje-online.orgdefined by the WHO established cut-offs (23), and/or of
a BMD low for age (i.e. Z-score !K1.0) and/or a
history of an adult fragility fracture (hip, vertebrae
T5–L4, wrist, ribs, and proximal humerus) caused by
low trauma, such as falling from a standing height or
less) (Fig. 1). The characteristics of the whole sample
of the patients evaluated for the enrollment are reported
in Table 1.
A written informed consent before entering the study,
which was approved by the Local Ethical Committee
and in accordance with the Declaration of Helsinki II,
was obtained from all patients.
Since the aim of our study was to investigate the true
prevalence of the different subclinical contributors to
low BMD and/or fragility fracture, we decided to exclude
all subjects affected with an already known or clinically
evident cause of secondary osteoporosis at the time
of the first visit. Therefore, 427 patients (317 females
and 110 males) were not considered eligible for the
study on the basis of the following exclusion criteria:
a history of gastrectomy, bowel disease or resection,
eating disorders, alcoholism, malnutrition, premature
menopause (before 40 years of age), prolonged
premenopausal amenorrhea (R1 year), a period of
prolonged immobility (R3 months), PHPT, overt
endogenous hypercortisolism, hyperthyroidism, liver
diseases, rheumatoid arthritis or other rheumatologicCeliac
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Table 1 Characteristics of the 1095 patients evaluated for the
enrollment.
Patients evaluated
for the enrollment
(nZ1095)
Females 943 (86.1)
Age (years) 62.9G12.3 (19–91)
BMI (kg/m2) 24.4G3.6 (16.1–38.6)
Patients with already known
Primary hyperparathyroidism 25 (2.3)
Hyperthyroidism 23 (2.1)
Overt hypercortisolism 3 (0.3)
Hypogonadisma 26 (2.3)
Celiac and other bowel diseases 19 (1.7)
Liver diseases 60 (5.5)
Multiple myeloma 4 (0.4)
Paget’s disease of bone 3 (0.3)
Patients with history of organ
transplantation
46 (4.2)
Patients with other diseases influencing
bone metabolism
50 (4.6)
Patients with medication history of
glucocorticoid therapy (O1 month)
16 (10.6)
Patients with medication history of other
drugs influencing bone metabolismb
52 (4.7)
Patients with apparent primary
osteoporosis
668 (61)
aIn males with already known hypogonadism, in females with prolonged
premenopausal amenorrhea (R1 year) or premature menopause (before
40 years of age).
bSystemic chemotherapy, current anticonvulsant therapy, TSH-suppressive
L-thyroxine therapy, heparin, methotrexate, cyclosporine, isoniazid, lithium,
GnRH agonists or antagonists and aromatase inhibitors.
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nine clearance estimated by Cockcroft–Gault equation
!60 ml/min) (24), Paget’s disease, osteomalacia, child-
hood rickets, advanced Parkinson’s disease, sarcoidosis,
hematologic malignancy, Gaucher’s disease and meta-
static cancer (Table 1). We also excluded all subjects
(nZ7) with alcohol consumption R12 U/day, and
those with medication history of systemic chemother-
apy, prolonged glucocorticoid use (O1 month), current
anticonvulsant therapy, TSH-suppressive L-thyroxine
(T4) therapy, heparin, methotrexate, cyclosporine,
isoniazid, lithium, GnRH agonists or antagonists,
aromatase inhibitors and other drugs known to affect
bone metabolism (Table 1).
Among theremaining 668 patients(620femalesand 48
males) who were eligible for the study, 66 (57 females and
nine males) did not complete the study protocol.
A full personal history was collected from the 602
eligible patients who completed the study protocol (563
females and 39 males). The availability of testing results
was mandatory for the enrollment.
Moreover, family history (first- and second-degree
relatives) of osteoporosis or fragility fractures, history
of nephrolithiasis, cigarette smoking (ever smoked
vs never smoked) and number of falls within the last
12 months (0, 1 and O1) were obtained from all sub-
jects. All subjects were asked about quantity and typeof alcoholic drinks consumed and data were converted
as units per day (8 g of pure alcohol) (25).
The patients were also asked about previous clinical
fragility fractures at spine, ribs, wrist and hip and
proximal humerus. Fractures of shoulder, pelvis, skull,
jaw, coccyx, phalanx, ankle, cervical and thoracic
vertebrae (C1 to T4), toes and fingers and of posterior
arches of the vertebra were not considered as osteo-
porosis-related fractures and were excluded from the
analysis. In all patients, the presence of previous
fragility fractures was ascertained by self-report and
no additional validation of this information was
conducted. Calcium intake, expressed as milligrams
per day, was assessed using a validated questionnaire
(26). In particular, usual calcium intake coming from
some selected calcium-rich foods (milk and dairy
products) was estimated by a 7-day food frequency
questionnaire. The foods checked include milk, aged
cheese, soft cheese, cottage cheese and yoghurt. The
portion sizes were quantified by means of household
measures (slices and cups). To standardize the slice
weight, three cardboard samples of different sizes were
used (about 100, 50 and 25 g). The number of
standardized servings was assessed, each containing
w300 mg of calcium (a 250 ml cup of milk or yoghurt,
a portion of about 100 g of cottage cheese, a 50 g slice
of soft cheese and a 25 g slice of aged cheese) (26).
In all patients height and weight were measured and
BMI was calculated.Methods
All patients underwent the following testing on a blood
venous sample obtained after overnight fasting under
a free diet: complete blood cell count and differential,
serum calcium, phosphate, serum creatinine, alkaline
phosphatase, g-glutamyl transpeptidase, erythrocyte
sedimentation rate, C-reactive protein, serum protein
electrophoresis, serum aminotransferases, intact
plasma parathyroid hormone (PTH, normal values
10–55 ng/l), 25OHVitD, TSH, total serum IgA, IgA
antitissue transglutaminase and IgA endomysial
antibodies were measured. On a separate day, the
serum cortisol levels after 1-mg overnight dexametha-
sone suppression test (1-mg DST) were measured in all
subjects. In all males serum total testosterone was
evaluated. Urinary calcium, creatinine and calcium
clearance were measured in 24-h urine collections.
All patients with 25OHVitD levels below 75 nmol/l
received supplementation. An oral bolus of 100 000
or 300 000 IU of cholecalciferol was administered
in patients with 25OHVitD levels between 25 and
75 nmol/l and below 25 nmol/l respectively (15).
Serum calcium, 25OHVitD and PTH and urinary
calcium and creatinine in 24-h urine collections were
re-evaluated once 25OHVitD levels above 75 nmol/l
were achieved, at least 1 month after cholecalciferol
administration. We decided to use 25OHVitD levelswww.eje-online.org
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supplementation, since several evidences suggest that,
below this 25OHVitD concentration, the calcium
absorption and PTH levels are reduced and increased
respectively, while above this threshold they reach a
steady state (27, 28). In all subjects, after vitamin D
supplementation, 25OHVitD levels were between 75
and 200 nmol/l.
Dual energy X-ray absorptiometry (DXA) scans were
carried out to measure BMD at the spine and hip.
Seventy-nine percent of subjects underwent DXA
evaluation at our Hospital (Hologic Discovery, Waltham
MA, USA) at lumbar spine (LS; in vivo precision 1.0%),
total femur (FT; in vivo precision 1.7%) and femoral neck
(FN; in vivo precision 1.8%), while the remaining 21%
had measurements on other instruments at other
centers (Hologic Discovery and Lunar GE). The different
machines were not calibrated against the same
phantom. However, to accommodate results from
different machines and manufacturers, densitometry
results were recorded as T- and Z-scores (S.D. from young
and age-matched normals respectively) using the
manufacturer’s normative reference groups (29). Data
from LS scans were used only if at least three vertebrae
were visualized without interfering artefacts. Fractured
vertebrae were excluded from BMD measurement.
In 45 patients LS BMD could not be evaluated.
Conventional spinal radiographs in lateral and
anteroposterior projection (T4–L4) were obtained at
baseline in all subjects with standardized technique.
Two trained physicians, who were blinded to BMD and
hormonal data, independently reviewed the radio-
graphs, and they discussed questionable cases to agree
on a diagnosis. The interrate reliability between the two
radiologists was good (kZ0.8).
Vertebral fractures were diagnosed on visual inspec-
tion using the semiquantitative (SQ) visual assessment
previously described by Genant et al. (30). According to
this technique, fractures assessed on lateral thoraco-
lumbar spine radiographs were defined as reductions
of more than 20% in anterior, middle or posterior
vertebral height. From lateral spine radiographs, 13
vertebrae from T4 to L4 were assessed visually as intact
(SQ grade 0) or as having approximately mild (20–25%
compression), moderate (25–40% compression) or
severe (O40% compression) deformity (SQ grades 1, 2
and 3 respectively). Subsequently, for each subject, the
spinal deformity index (SDI) was calculated by summing
the SQ grade for each vertebra (SDIZSQT4C.C
SQT12CSQL1C.CSQL4) (31). For example, an SDI
of 3 can mean one grade 3 fracture or three grade 1
fractures.Abnormal laboratory tests
Participants with altered TSH levels were tested for free
T4 (fT4), antithyroglobulin, antithyroperoxidase and
anti-TSH receptor (TRAb) antibodies. Overtwww.eje-online.orghyperthyroidism was defined by TSH levels
!0.3 mU/ml (mU/l) with elevated fT4 and subclinical
hyperthyroidism by TSH levels !0.3 mU/ml
(!0.3 mU/l) with normal fT4 levels. Total calcium was
corrected for serum albumin according to the formula:
total calcium (mg/dl)C(4.4Kalbumin (mg/dl))!0.8
(reference interval 8.4–10.2 mg/dl, 2.1–2.55 mmol/l)
(32). Patients with increased serum calcium levels
together with increased or inappropriately normal PTH
levels were tested for ionized serum calcium levels. PHPT
was diagnosed by hypercalcemia and elevated or
inappropriately normal PTH levels, after the evaluation
of calcium clearance:creatinine clearance ratio, in order
to rule out familial hypocalciuric hypercalcemia (21).
In patients with normal IgA antitissue transglutami-
nase and IgA endomysial antibodies and a selective
IgA deficiency, IgG antitissue transglutaminase
antibodies and IgG endomysial antibodies were eval-
uated. Patients with positive serologic tests underwent
duodenal biopsy. The diagnosis of celiac disease was
established in the presence of the typical histological
findings (33).
Participants with 1-mg DST O50 nmol/l underwent
further diagnostic investigations (i.e. serum cortisol
levels measured at 0900 h after 2 days of low-dose
(0.5 mg every 6 h) dexamethasone suppression, two
measurements of 24-h urinary free cortisol and
measurement of ACTH at 0800 h). SH was diagnosed
in the presence of cortisol level O50.0 nmol/l after a
2-day low-dose DST and/or elevated 24-h urinary free
cortisol in the absence of signs or symptoms of cortisol
excess, including moon facies, striae rubrae, skin
atrophy or buffalo hump (34).
Males with at least two determinations of serum
total testosterone levels below the lower limit of
the normal range for age (!10.4 and !6.9 nmol/l,
before and after the age of 70 respectively) were
classified as hypogonadic and underwent additional
evaluations (35).
The diagnosis of monoclonal gammopathy of
undetermined significance (MGUS) required a serum
monoclonal protein, no evidence of other B-cell pro-
liferative disorders and no end-organ damage due to the
plasma cell proliferative process (i.e. bone lesions,
hypercalcemia, renal insufficiency and anemia) (36, 37).
Hypercalciuria was established in the presence of
urinary calcium excretion O0.1 mmol/kg body weight
(22), both in men and women, in at least two 24-h
urinary samples, in conditions of normal dietary sodium
(1.5 g/day between 19 and 30 years of age, 1.3 g/day
between 31 and 50 years of age and 1.2 g/day older
than 51 years of age), protein (46 g/day for females and
56 g/day for males older than 19 years of age) and
calcium intake (1.0 g/day for males and females
between 19 and 50 years of age, 1.2 g/day for females
older than 51 years of age) (38). After the exclusion of
known causes of hypercalciuria (i.e. PHPT, sarcoidosis,
Cushing’s syndrome, cancer, excess vitamin D intake,Downloaded from Bioscientifica.com at 10/17/2019 02:30:52PM
via Universita Degli Studi di Milano
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or renal tubular acidosis), the diagnosis of IH was
established.
Patients with polyarticular pain and elevated erythro-
cyte sedimentation rate and/or C-reactive protein
underwent rheumatologic evaluation, in order to
exclude an autoimmune rheumatologic disease. In
selected patients serum tryptase levels and bone
marrow examination were needed in order to exclude
mastocytosis and multiple myeloma.Table 2 Characteristics of the 602 enrolled patients. Data are
meanGS.D. with range or percentage in parenthesis.
Patients enrolled (nZ602)
Females 563 (93.5)
Age (years) 65.4G10.1 (33 to 89)
BMI (kg/m2) 24.6G3.6 (18 to 38.6)
No. of patients with history of current
or previous smoking
189 (31.4)
No. of patients experiencing falls
(0/1/2)
515/64/23 (85.5/10.6/3.8)
Dietary calcium intake (mg/day) 533G254 (50 to 2000)
No. of patients with history of
nephrolithiasis
101 (16.8)
No. of patients with family history of
osteoporosis
297 (49.3)
No. of patients with family history of
fragility fractures
126 (20.9)
No. of patients with hypovitaminosis
D (0/1/2)
176/364/62 (29.2/60.5/10.3)
LS BMD (Z-score) K1.03G1.14 (K4.2 to 3.1)
FT BMD (Z-score) K0.66G0.9 (K3.5 to 2.1)
FN BMD (Z-score) K0.74G0.86 (K3.5 to 2.0)
No. of patients with T-score%K2.5
at any site
412 (68.4)
No. of patients with history of clinical
fractures
136 (22.6)
SDI 2.2G3.4 (0 to 27)
SDIR1 335 (55.6)
No. of patients with clinical and/or 361 (60)Statistical analysis
Statistical analysis was performed by SPSS version 18.0
statistical package (SPSS, Inc.). The normality of
distribution was checked by Kolmogorov–Smirnov
test. The results are expressed as meanGS.D. if not
differently specified. The comparison of continuous
variables between patients with and without subclinical
contributors to low BMD and/or fragility fractures
was performed using Student’s t-test or Mann–Whitney
U test, as appropriate. The univariate general linear
modeling has been used to compare SDI values between
patients to adjust for age variables between patients
with and without subclinical contributors to low BMD
and/or fragility fractures, if needed. Categorical vari-
ables were compared by c2 test.
The logistic regression analysis assessed the associ-
ation between the presence of subclinical contributors
to low BMD and/or fragility fractures including and
excluding hypovitaminosis D (dependent variable)
and the variables that were found to be significantly
different between patients with and without subclinical
contributors to low BMD and/or fragility fracture
(independent variables). Then, for the continuous
independent variables, the receiver operating charac-
teristic (ROC) curve analysis was performed to assess
their best cut-offs for individuating patients with
subclinical contributors to low BMD and/or fragility
fracture besides hypovitaminosis D. Finally, we assessed
the sensitivity and specificity and overall accuracy
for detecting patients with subclinical contributors
to low BMD and/or fragility fracture of a diagnostic
two-step protocol, in which a first-line testing is
performed in all patients and a second-line testing is
performed only in patients showing the characteristics
that were found by the logistic regression analysis to
be associated with the presence of a subclinical contri-
butor of low BMD and/or fragility fracture (using for
the continuous variables the cut-offs individuated
by the ROC curve analysis). Values of P!0.05 were
considered significant.morphometric fractures
Fall: 0, no fall within previous 12 months; 1, one fall within previous 12
months; 2, greater than or equal to two falls within previous 12 months;
hypovitaminosis D: 0, 25-hydroxyvitamin D at baseline R75 nmol/l; 1,
25-hydroxyvitamin D at baselineR25 and!75 nmol/l; 2, 25-hydroxyvitamin
D at baseline!25 nmol/l; BMD, bone mineral density; SDI, spinal deformity
index; SDI R1, patients with at least one morphometric vertebral fracture.Results
The final sample of patients enrolled in the study and
screened for the presence of subclinical contributorsto low BMD and/or fragility fracture was composed
of 602 patients (563 females and 39 males; Fig. 1).
The characteristics of these patients are shown in
Table 2. At baseline, 70.8 and 45.3% of patients had
25OHVitD levels below 75 and 50 nmol/l respectively.
Among these, 10.3% of patients had 25OHVitD below
25 nmol/l.
The prevalence of subclinical contributors to low
BMD and/or fragility fracture is reported in Table 3.
A status of hypovitaminosis D (25OHVitD levels
!75 nmol/l) was found to be the most prevalent
contributor of low BMD and/or fragility fracture
(Table 3). After vitamin D supplementation, a diagnosis
of additional subclinical contributors to low BMD
and/or fragility fracture apart from hypovitaminosis D
was made in 271 subjects (45%). However, given
its high prevalence even in the healthy population
(39, 40, 41), hypovitaminosis D might be considered
a concomitant cause of secondary osteoporosis. In
addition, we do not have information regarding the
vitamin D status of our patients before the study entry.
Therefore, in Table 3 we also report the prevalence
of each subclinical contributor to low BMD and/or
fragility fracture besides hypovitaminosis D.www.eje-online.org
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Table 3 Hypovitaminosis D and other additional contributors to low
BMD and/or fragility fracture in patients affected with apparently
idiopathic primary osteoporosis after vitamin D supplementation.
Data are number of patients with percentage in parentheses.
Main contributors of low
BMD and/or fragility
fracture (no. of patients)
All enrolled
patients
(nZ602)
Patients with
hypovitaminosis D
(nZ426)
Hypovitaminosis D 426 (70.8) –
Idiopathic hypercalciuria 205 (34.1) 47 (34.5)
Primary hyperparathyroidism 27 (4.5) 23 (5.4)
Subclinical and overt
hyperthyroidism
8 (1.3) 5 (1.2)
Subclinical hypercortisolism 8 (1.3) 6 (1.4)
Celiac disease 7 (1.2) 7 (1.6)
Hypogonadism 2 (5.1)a 2 (9.1)a
MGUS 14 (2.3) –
Low calcium intake (10) 10 (1.7) –
Hypovitaminosis D, 25-hydroxyvitamin D !75 nmol/l; MGUS, monoclonal
gammopathy of undetermined significance.
aAmong 22 male patients.
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we found that before vitamin D supplementation IH was
present in 137 patients (22.8% of the whole sample),
while after vitamin D supplementation, IH was
diagnosed in an additional 68 patients. Thus, IH was
found in 205 patients, about one out of three patients
with apparent idiopathic primary osteoporosis, repre-
senting 75.6% of subclinical contributors to low BMD
and/or fragility fracture besides hypovitaminosis D.
Most of these patients well tolerated the therapy with
hydrochlorothiazide (25 mg daily), which is suggested
in order to reduce urinary calcium excretion.
Similarly, before vitamin D supplementation, PHPT
was found in 22 subjects (3.7% of the whole sample,
all females). After vitamin D supplementation, PHPT
was diagnosed in an additional five subjects (one male
and four females). Therefore, the prevalence of PHPT
among the whole sample of 602 patients was 4.5%
(27 patients). Fifteen were surgically treated and in all
subjects PTH and serum and urine calcium normalized.
Hypogonadism was diagnosed in 2 out of 39 male
patients (5.1% of male patients). All these patients
initially denied, at medical history, alteration of sexual
function. Both patients, after the exclusion of prostatic
diseases, started testosterone substitutive therapy.
Hyperthyroidism was diagnosed in 1.3% of patients
(subclinical in seven patients and overt in one patient).
All patients underwent neck ultrasound, radioiodine
uptake and TRAb antibodies were measured. In three
patients (one overt and two subclinical) a Graves–
Basedow disease was diagnosed. One patient underwent
radioactive iodine treatment and the remaining two
started medical treatment with methimazole. In the
other five patients we found a partial autonomous
multinodular goiter. Three patients underwent radio-
iodine treatment and two underwent surgery.
SH was found in 1.3% of patients. Thirty-five out of
602 patients failed to suppress cortisol levels after 1-mgwww.eje-online.orgDST and underwent additional tests. Eventually, SH was
confirmed in eight patients (seven patients had an
ACTH-independent SH due to an adrenal mass and one
patient had an ACTH-dependent SH of pituitary origin).
To date, four SH patients with a unilateral adrenal mass
underwent surgery and in all a steroidal replacement
therapy was needed.
Among the 602 enrolled patients, 13 underwent
small bowel biopsy because of the subsequent findings:
positive values of IgA antitissue transglutaminase
and/or IgA endomysial antibodies (ten patients),
gastrointestinal symptoms without serological altera-
tions (one patient), and severe 25OHVitD deficit hardly
correctable (two patients). Among these 13 patients,
a histological diagnosis of celiac disease was made
in seven (1.2%).
The presence of MGUS was found to be the only
possible cause of low BMD and/or fragility fracture in
14 patients (2.3% of the 602 enrolled patients). Five
patients with MGUS, with severe osteoporosis, without
other abnormalities in the laboratory’s tests, underwent
bone marrow examination. In all patients the presence
of multiple myeloma was excluded.
Ten patients (six males and four females) were
found to have secondary hyperparathyroidism, without
evidence of hypovitaminosis D, gut malabsorption,
hypercalciuria or reduced kidney function. All patients
were older than 70 years of age and had a calcium
intake lower than 150 mg/day.
Eighteen patients (2.9%), presenting polyarticular
pain and elevated erythrocyte sedimentation rate
and/or C-reactive protein levels, underwent rheumato-
logic evaluation. No patients were diagnosed as having
a rheumatologic disease. In 23 patients with severe
osteoporosis (i.e. SDI R10), among the 331 without
subclinical contributors to low BMD and/or fragility
fracture, serum tryptase levels were determined. Two
patients with a slight increase of tryptase levels
underwent bone marrow examination and in both the
diagnosis of mastocytosis was excluded.
By separately analyzing premenopausal females
(nZ13), we found that 11 were affected with subclinical
contributors to low BMD and/or fragility fracture
besides hypovitaminosis D (nine with IH and two with
SH), while two were not. Among these patients nine
and three subjects had 25OHVitD levels below 75 and
25 nmol/l respectively. Seven out of the 11 premeno-
pausal patients with subclinical contributors to low
BMD and/or fragility fracture besides hypovitaminosis D
had an asymptomatic and/or clinical fragility fracture,
while the two premenopausal patients without sub-
clinical contributors to low BMD and/or fragility
fracture were not fractured. Table 4 summarizes the
clinical characteristics of patients affected with hypovi-
taminosis D and with each subclinical contributor of
secondary osteoporosis to low BMD and/or fragility
fracture besides hypovitaminosis D.Downloaded from Bioscientifica.com at 10/17/2019 02:30:52PM
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Table 4 Clinical characteristics of patients with the main subclinical contributors to low BMD and/or fragility fracture. Data are meanGS.D.
with range or percentage in parenthesis.
Subclinical contributors to low
BMD and/or fragility fracture Females Age
Z-score
!K1.0a
T-score
!K2.5a
Prevalence
of fragility
fracture
Prevalence of
hypovitaminosis D
Hypovitaminosis D alone (nZ236) 217 (91.9) 67.6G9.7 (36–89) 149 (63.1) 162 (68.6) 148 (62.7) –
Idiopathic hypercalciuria (nZ205) 195 (95.1) 62.6G9.7 (33–86) 146 (71.2) 143 (69.8) 128 (62.4) 147 (71.7)
Primary hyperparathyroidism (nZ27) 26 (96.3) 69G10.5 (48–89) 20 (74.1) 22 (81.5) 20 (74.1) 23 (85.2)
Hyperthyroidism (nZ8) 8 (100) 74.3G7 (63–83) 4 (50) 7 (87.5) 8 (100) 5 (62.5)
Subclinical hypercortisolism (nZ8) 7 (87.5) 60.3G15 (38–80) 7 (87.5) 7 (87.5) 7 (87.5) 6 (75)
Celiac disease (nZ7) 6 (85.7) 67.9G9.1 (56–78) 5 (71.4) 6 (85.7) 5 (71.4) 7 (100)
Hypovitaminosis D, 25OHVitD levels !75 nmol/l.
aAt any site.
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between the whole group of patients with and without
subclinical contributors of low BMD and/or fragility
fracture is reported in Table 5. Comparing patients with
subclinical contributors of low BMD and/or fragility
fracture other than hypovitaminosis D with patients
without them, we found that the patients in the former
group were younger, had a lower BMI and BMD at spine
and femur and a higher prevalence of clinical and/or
morphometric fragility fractures. The two groups were
comparable for gender, history of current or previous
smoke, frequency of falls, dietary calcium intake, history
of nephrolithiasis, family history of osteoporosis and
fragility fractures, SDI, and prevalence of hypovitami-
nosis D and osteoporosis. Comparing patients with
subclinical contributors of low BMD and/or fragility
fracture including hypovitaminosis D with patients
without them, we did not find differences in gender,
age, BMI, history of current or previous smoking,
frequency of falls, dietary calcium intake, history of
nephrolithiasis, family history of osteoporosis and
fragility fractures and BMD at spine and femur, while
the former group showed higher prevalence of osteo-
porosis, clinical and morphometric vertebral fractures
and SDI.
The logistic regression analysis showed that the
presence of subclinical contributors to low BMD
and/or fragility fracture besides hypovitaminosis D
was associated inversely with age and BMI and directly
with the presence of a fragility fracture (clinical and/or
morphometric), but not with BMD (Table 6A). When
including hypovitaminosis D among the subclinical
contributors to low BMD and/or fragility fracture only,
the presence of a fragility fracture (clinical and/or
morphometric) was associated with the presence of
subclinical contributors to low BMD and fragility
fractures (Table 6B). The SDI was not associated with
any specific contributor of low BMD and/or fragility
fracture. Then, the ROC curve analysis, performed to
assess the best threshold values of BMI and age for
predicting the presence of subclinical contributors
to low BMD and/or fragility fracture besides hypo-
vitaminosis D, showed that the cut-offs with the bestcompromise between sensitivity and specificity were
24 g/cm2 for BMI and at 65 years for age. Therefore,
on the basis of the logistic regression and ROC curve
analyses, the presence of a fragility fracture, a BMI
!24 g/cm2 and an age !65 years were found to be
the variables associated with the presence of subclinical
contributors of low BMD and/or fragility fracture
besides hypovitaminosis D.
Following the Italian guidelines (42), in patients with
reduced BMD and/or fragility fracture the assessment
of PTH, 25OHVitD, TSH, 1-mg DST, and IgA antitissue
transglutaminase and endomysial levels is not included
among the routine first-line screening tests and it is
considered a second-line test to be reserved for patients
at high risk of having a secondary cause of osteoporosis.
In our sample, if we had performed complete blood
cell count and differential count, serum calcium,
phosphate, serum creatinine, alkaline phosphatase,
erythrocyte sedimentation rate, serum protein electro-
phoresis and 25OHVitD as first-line screening tests in all
patients and the second-line tests (i.e. PTH, TSH, 1-mg
DST, and IgA antitissue transglutaminase and endomy-
sial levels) in patients with abnormal screening tests
and/or the concomitant presence of BMI !24 g/cm2,
age !65 years and a fragility fracture, after the
normalization of 25OHD levels, we would have correctly
individuated 549 out of the 602 patients (accuracy
91.2%). Indeed, if this protocol had been applied, 236
and 313 subjects would have been correctly diagnosed
as affected (true positives) or not affected (true
negatives) with a subclinical contributor of low BMD
and/or fragility fracture besides hypovitaminosis D
respectively while 21 affected patients would have
been missed (false negatives, sensitivity 91.8%) and
32 patients not affected would have been erroneously
considered at risk (false positives, specificity 90.7%).
In total, 61.9 and 85.7% of false-negative patients
showed a Z-score !K1.0 and the presence of at least
one fragility fracture respectively.
If the second-line tests had been performed in patients
with abnormal first-line tests and/or with two out
of the presence of BMI !24 g/cm2, age !65 years
and a fragility fracture, the sensitivity for detecting awww.eje-online.org
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Table 5 Characteristics of patients with and without subclinical contributors to low BMD and/or fragility fracture, among the whole sample of 602 enrolled patients. Data are meanGS.D.
with range or percentage in parenthesis.
Patients with subclinical
contributors of low BMD
and/or fragility fracture
Patients without subclini-
cal contributors of low
BMD and/or fragility
fracture
Patients with subclinical
contributors of low
BMD and/or fragility
fracture other than
hypovitaminosis D
Patients without subclini-
cal contributors of low
BMD and/or fragility
fracture other than
hypovitaminosis D
Variables nZ493 (81.9) nZ109 (18.1) P nZ271 (45) nZ331 (55) P
Females 459 (93.1) 104 (95.4) 0.375 254 (93.7) 309 (93.4) 0.853
Age (years) 65.6G10.2 (33 to 89) 64.6G9.4 (38 to 84) 0.378 64.1G10.3 (33 to 89) 66.4G9.7 (36 to 89) 0.004
BMI (kg/m2) 24.6G3.7 (18.5 to 38.6) 24.8G3.2 (17.3 to 35.4) 0.488 23.8G3.2 (18.5 to 37.8) 25.3G3.7 (18 to 38.6) 0.0001
No. of patients with history of current or
previous smoking
147 (29.8) 42 (38.5) 0.076 82 (30.3) 107 (32.3) 0.586
No. of patients experiencing falls (0/1/2) 416/55/22 (84.4/11.2/4.5) 99/9/1 (90.8/8.3/0.9) 0.13 240/21/10 (88.6/7.7/3.7) 275/43/13 (83.1/13.0/3.9) 0.111
Dietary calcium intake (mg/day) 527.9G242 (50 to 1900) 554G301 (50 to 2000) 0.332 535G231 (50 to 1600) 530G272 (50 to 2000) 0.844
No. of patients with history of
nephrolithiasis
83 (16.8) 18 (16.5) 0.935 51 (18.8) 50 (15.1) 0.225
No. of patients with family history of
osteoporosis
237 (48.1) 60 (55) 0.188 137 (50.6) 160 (48.3) 0.589
No. of patients with family history of
fragility fractures
106 (21.5) 30 (27.5) 0.174 60 (22.1) 76 (23) 0.811
No. of patients with hypovitaminosis D 426 (86.4) 0 (0.0) 0.0001 200 (73.8) 226 (68.3) 0.138
Lumbar spine BMD (Z-score) K1.07G1.12 (K4.2 to 2.9) K0.86G1.21 (K3.3 to 3.1) 0.083 K1.22G1.14 (K4.2 to 2.1) K0.88G1.11 (K3.4 to 3.1) 0.0001
Total femur BMD (Z-score) K0.67G0.93 (K3.5 to 2.1) K0.61G0.77 (K2.9 to 1.5) 0.538 K0.76G0.90 (K3.5 to 2.1) K0.58G0.90 (K3.2 to 1.8) 0.013
Femoral neck BMD (Z-score) K0.75G0.9 (K3.5 to 2) K0.71G0.7 (K2.7 to 1.3) 0.669 K0.81G0.86 (K3.5 to 2) K0.68G0.87 (K3.5 to 1.7) 0.05
No. of patients with T-score %K2.5
at any site
348 (70.6) 64 (58.7) 0.016 196 (72.3) 216 (65.3) 0.063
No. of patients with history of clinical
fractures
111 (22.5) 15 (13.8) 0.042 67 (24.7) 59 (17.8) 0.038
SDIa 2.4G3.4 (0 to 23) 1.4G3.4 (0 to 27) 0.01 2.2G0.2 (0 to 14) 2.3G3.8a (0 to 27) 0.32
No. of patients with clinical and/or
morphometric fractures
318 (64.5) 43 (39.4) 0.0001 181 (66.8) 180 (54.4) 0.002
Fall: 0, no fall within previous 12 months; 1, one fall within previous 12 months; 2, greater than or equal to two falls within previous 12 months; hypovitaminosis D, 25-hydroxyvitamin D at baseline!50 nmol/l;
BMD, bone mineral density; SDI, spinal deformity index; SDI R1, patients with at least one morphometric vertebral fracture.
aCorrected for age by general linear modeling.
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Table 6 Odds ratio (OR) for detecting the presence of subclinical
contributors to low BMD and/or fragility fracture other than
hypovitaminosis D (A) and including hypovitaminosis D (B) for
potential risk factors using the multivariable logistic regression model.
OR 95% CI P
A
Age (1 year decrease) 1.02 1–1.04 0.04
BMI (1 kg/m2 decrease) 1.1 1.05–1.17 0.0001
Presence of fragility fractures
(presence vs absence)a
1.89 1.31–2.73 0.01
Z-score LS (1 S.D. decrease) 1.1 0.92–1.3 0.296
B
Age (1 year decrease) 1.01 0.98–1.03 0.62
BMI (1 kg/m2 decrease) 1.02 0.95–1.08 0.638
Presence of fragility fractures
(presence vs absence)a
2.51 1.59–3.96 0.0001
Z-score LS (1 S.D. decrease) 4.01 0.92–1.41 0.88
aClinical or morphometric fracture; Z-score LS, BMD at spine expressed as
Z-score.
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fracture besides hypovitaminosis D would have
increased to 96.1%, while the specificity would have
decreased to 60.3% (accuracy 75.6%).Discussion
To our knowledge, this is the largest study aimed to
assess the true prevalence of subclinical contributors to
low BMD and/or fragility fracture. At variance with
previous similar studies (3, 4, 5, 6, 7, 18, 19, 20), the
present one evaluates the prevalence of subclinical
contributors to low BMD and/or fragility fracture even
after correction of hypovitaminosis D.
Our study indicates that the most prevalent sub-
clinical contributor to low BMD and/or fragility fracture
is hypovitaminosis D, being present in 70.8% of our
sample. Without considering hypovitaminosis D, a
subclinical contributor to low BMD and/or fragility
fracture is present in 45% of patients with apparent
primary osteoporosis, without any difference between
genders. The presence of subclinical contributors to low
BMD and/or fragility fracture besides hypovitaminosis D
was associated inversely with age and BMI and directly
with the presence of clinical and/or morphometric
fractures, regardless of BMD. IH was diagnosed in about
one out of three patients with apparent primary
osteoporosis, and represented about 80% of the
subclinical contributors to low BMD and/or fragility
fracture in addition to hypovitaminosis D.
Among the other subclinical contributors besides
hypovitaminosis D, PHPT, hyperthyroidism, SH, celiac
disease, MGUS and male hypogonadism were found in
4.5, 1.3, 1.3, 1.2, 2.3 and 5.1% of patients respectively.
In addition, the correction of hypovitaminosis D
consented to individuate 68 patients with IH (out of
205, 33.2%) and five with PHPT (out of 27, 18.5%),who had not been diagnosed before vitamin D
supplementation. This is important due to the high
prevalence of hypovitaminosis D in Italy, even in the
healthy population (39, 40, 41).
Finally, the presence of subclinical contributors to low
BMD and/or fragility fracture besides hypovitaminosis D
is more frequent in patients younger than 65 years of
age, with a BMI below 24 kg/m2 and a fragility fracture.
Our study shows a higher prevalence of subclinical
contributors to low BMD and/or fragility fracture
other than hypovitaminosis D than previously reported
(3, 7), possibly because of the extensive laboratory
investigations used in the present study. Moreover,
the lower cut-off used in the previous reports to define
the vitamin D deficiency may also have played a role
in underestimating the true prevalence of the sub-
clinical contributors to low BMD and/or fragility
fracture (3, 4, 20).
At variance with previous studies (1, 43), we did not
find a higher prevalence of subclinical contributors
of low BMD and/or fragility fracture in male than in
female subjects. This may be due to the fact that we
excluded patients with already known causes of
secondary osteoporosis. In keeping with this, in the
only previous study with a similar design, the authors
did not find a difference in the prevalence of secondary
osteoporosis between male and female patients (7).
A novel finding is that the prevalence of clinical
fragility fractures and/or morphometric vertebral
fractures is higher in patients with other subclinical
contributors to low BMD and/or fragility fracture
besides hypovitaminosis D than in patients without
them. Indeed, this point was not assessed in the study of
Tannenbaum et al. (3), while in two other studies only
fractured subjects were included (6, 7). The presence
of a fragility fracture was found to be associated with
the presence of subclinical contributors to low BMD
and/or fragility fracture regardless of BMD, confirming
that, in these patients, BMD explains only in part the
increased fracture risk (1, 2, 44).
The prevalence of IH and PHPT in the present report
was higher than previously reported (3, 4, 5, 6, 7, 20, 43),
with the exception of the study of Romagnoli et al. (5).
This may be explained by the fact that the previous
studies used different criteria to define hypercalciuria and
did not evaluate serum and urinary calcium levels after
hypovitaminosis D correction (3, 4, 5, 6, 20). Indeed,
the prevalence of IH we found before 25OHVitD levels
normalization was definitely lower (22.8%) than that
found after the achievement of normal 25OHVitD
levels (33.2%). Similarly, the normalization of 25OHVitD
levels led to an increase of the PHPT prevalence.
As compared with the present one, previous studies
found a similar (20), lower (4, 5, 33) or higher pre-
valence (6, 7) of hyperthyroidism and celiac disease
among patients with low BMD. The ‘real life’ population
enrolled in the present study (i.e. patients with low BMD
and/or clinical and/or morphometric fragility fractures)www.eje-online.org
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finding the highest prevalence of these disorders, in fact,
included only osteoporotic patients (33) or those with
clinical fractures (6, 7).
Similarly, the lower prevalence of male hypogonadism
than previously reported (7, 20) could be explained
considering that in the previous studies only patients
with clinical fractures (7) or osteoporosis (20) were
evaluated. However, the small sample of male patients
(possibly explained by the reduced awareness
of osteoporosis among males) could have biased
this result.
The different patients’ selection may also explain the
lower prevalence of SH as compared with previous
studies (16, 45). On the other hand, the very low SH
prevalence reported by other authors (3, 5) is related to
the use of urinary free cortisol as a screening test for
SH, instead of the more sensitive 1-mg DST (34).
In keeping with previous data (46), MGUS was found
in 2.3% of patients with apparent primary osteoporosis.
This is important since it seems to be associated with an
increased fracture risk (46, 47, 48). Finally, we made no
diagnosis of rheumatologic disease. This may result
from the fact that, in patients with a rheumatologic
disease, pain is the predominant symptom that leads to
prompt rheumatologic or orthopedic evaluation.
Overall, as compared with the previous reports, in
addition to the large sample studied, the advantage of
the present study is related to its ‘real life’ design that
consecutively included all patients with apparently
idiopathic bone density decrease and evaluated calcium
metabolism after normalization of vitamin D levels. This
consented to assess the prevalence of subclinical
contributors to low BMD and/or fragility fracture
besides hypovitaminosis D in a population not at
particular high risk, but, on the other hand, to reliably
estimate the prevalence of some disorders (i.e. PHPT and
IH), which may be often underscored in the presence of
hypovitaminosis D. Unfortunately, we do not have
information regarding the duration of the diseases
possibly leading to low BMD and/or fragility fracture
and the vitamin D status of our patients before the study
entry. In addition, since in Italy the hypovitaminosis D
is highly prevalent even in the healthy population
(39, 40, 41), we do not know in how many patients a
long-standing condition of hypovitaminosis D can be
reliably considered the main cause of low BMD and/or
fragility fracture. To overcome this limitation, the
prevalence of the subclinical contributors to low BMD
and/or fragility fracture was reported even without
considering hypovitaminosis D. Another limit of the
present study may be that its protocol is hardly
transferable in the clinical practice for because of the
high cost. However, it must be noted that the
biochemical workup we performed, with the exception
of PTH, 25OHVitD, TSH, 1-mg DST, and IgA antitissue
transglutaminase and endomysial, is considered the
routine first-line testing in patients with reduced BMDwww.eje-online.organd/or fragility fracture (48). On the basis of the present
data, in addition to the first-line evaluations, the
25OHVitD levels assessment seems mandatory in all
patients with low BMD and/or a fragility fracture, at
least in Italy. On the other hand, the results of the
present study show that patients showing the con-
comitant presence of three risk factors (age!65 years,
BMI !24 kg/m2 and a fragility fracture) are at higher
risk of being affected with a subclinical contributor to
low BMD and/or fragility fracture, regardless for BMD.
As a consequence, the second-line evaluations (i.e. PTH,
TSH, 1-mg DST and IgA antitissue transglutaminase
and endomysial) might be reserved to these latter
subjects, even if the first-line tests are negative. Indeed,
the application of this protocol would have consented to
correctly identifying more than 91% of patients affected
with a subclinical contributor to low BMD and/or
fragility fracture besides hypovitaminosis D (accuracy
91.2%), but 21 patients would have been missed
(sensitivity 91.8%) and in 32 patients the second-line
tests would have been useless (specificity 90.7%).
However, it is important to underline that the great
majority of the 21 false-negative patients had LS Z-score
!K1.0 and/or a fragility fracture. In addition, if the
second-line tests had been performed in patients with
abnormal first-line tests and/or two rather than three
risk factors among the presence of BMI!24 g/cm2, age
!65 years and a fragility fracture (i.e. a larger
population), only ten patients would have been missed
and the sensitivity for detecting a subclinical con-
tributor to low BMD and/or fragility fracture would
have increased to 96.1%, but at the expense of a
decrease in specificity (60.3%). In our opinion, on the
basis of the present data, a protocol including the first-
line screening tests in all patients with low BMD and/or
fragility fracture and the second-line tests in patients
with abnormal first-line tests and/or the concomitant
presence of three risk factors (age !65 years, BMI
!24 kg/m2 and a fragility fracture) may be suggested,
due to its good specificity (SP) and sensitivity (SN)
(Fig. 2). Indeed, even if the SN can be further increased if
the second-line tests are performed in patients with
abnormal first-line tests and/or two rather than three
risk factors, this protocol would have lower SP and,
therefore, higher costs. It must be observed, however,
that the high costs of the correct diagnosis of the
secondary causes of osteoporosis may be justified by
the possibility of avoiding the costs of the clinical
consequences of these disorders, since the treatment of
these conditions leads to a reduction in the fracture risk,
while their misdiagnosis can lead to inappropriate or
inadequate treatment (1, 2). For these reasons, in the
absence of cost-effectiveness data, it is difficult to
individuate from the present study the adequate
sensitivity and specificity of the first- and second-line
tests. However, considering that the great majority of
the 21 false-negative patients had LS Z-score !K1.0
and/or a fragility fracture, it is possible to hypothesizeDownloaded from Bioscientifica.com at 10/17/2019 02:30:52PM
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Abnormal first-line screening tests and/or all risk
factors out of the following:
-  Fragility fracture
-  BMI <24 g/cm2
-  Age <65 years
Patient with apparent idiopathic osteoporosis
-  Personal history
-  First-line biochemical screening tests: complete blood cell count and differential,
   serum calcium, phosphate, serum creatinine, alkaline phosphatase, erythrocyte
   sedimentation rate, serum protein electrophoresis and 25OHVitD
-  Thoracolumbar X-ray 
-  BMI
Normal first-line screening tests and <3 risk
factors out the following:
-  Fragility fracture
-  BMI <24 g/cm2
-  Age <65 years
Secondary cause
of osteoporosis
Low/moderate risk of secondary
osteoporosis
Treat the
underlying disease
High risk of secondary osteoporosis
Second-line biochemical screening tests:
PTH, TSH, 1-mg DST and IgA auto-antibodies antitissue
transglutaminase and endomysial levels
Idiopathic
osteoporosis
Treat osteoporosis
-  LS Z-score < –1.0
-  Fragility fracture
     Moderate risk
-  LS Z-score > –1.0
-  No fragility fracture
         Low risk
Figure 2 Algorithm for testing individuals with low BMD/fragility fractures for secondary causes derived from the results of the present study.
PTH, parathyroid hormone; 1-mg DST, 1-mg overnight dexamethasone suppression test; LS, lumbar spine; fragility fracture, low-trauma
clinical or asymptomatic fracture.
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first-line tests and/or three additional risk factors at the
first visit, but with a LS Z-score !K1.0 and/or a
fragility fracture, may lead to discover an initially
concealed subclinical form of secondary osteoporosis
(Fig. 2). Large longitudinal studies regarding the cost-
efficacy of the diagnostic protocols in patients with
osteoporosis are needed in order to determine the best
testing strategy for diagnosing the subclinical contribu-
tors to low BMD and/or fragility fracture.
In conclusion, our study demonstrates that in
patients with apparent primary osteoporosis: i) hypo-
vitaminosis D is a subclinical contributor to low
BMD and/or fragility fracture in more than 70% of
cases; ii) without considering hypovitaminosis D, a
subclinical contributor to low BMD and/or fragility
fracture is present in 45% of subjects, with IH
being the most frequent cause; and iii) 30% of IH
and 20% of PHPT patients are missed if the
diagnostic workup is performed in the presence of
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